Karim Fizazi, MD, PhD, on Darolutamide Treatment in Prostate Cancer: Helping Patients Assess Benefits vs Risks

Posted: Monday, June 10, 2019

Karim Fizazi, MD, PhD, of Institut Gustave Roussy, talks about what he tells his patients with nonmetastatic castrate-resistant prostate cancer about balancing the benefits with the risk of darolutamide-related side effects.